Keyphrases
Clinical Trials
100%
Assessing Risk
100%
Lapatinib
100%
Risk-benefit
100%
Combination Therapy
33%
Breast Cancer
33%
Overall Survival
22%
Adverse Event Rates
22%
Tolerability
11%
Adverse Events
11%
FDA-approved Drugs
11%
Metastatic Breast Cancer
11%
RECIST Criteria
11%
Progression-free Survival
11%
Objective Response
11%
PubMed
11%
Approved Indication
11%
Extended Indications
11%
Novel Chemotherapy
11%
Drug Manufacturer
11%
Solid Tumors
11%
Median Progression-free Survival
11%
Advanced Breast Cancer
11%
Oncologic
11%
Risk-benefit Analysis
11%
Off-label Indications
11%
Solid Cancer
11%
Repurposing
11%
Response Rate
11%
Cochrane
11%
Positive Outcomes
11%
Trial Characteristics
11%
Objective Response Rate
11%
Embase
11%
Pharmacology, Toxicology and Pharmaceutical Science
Lapatinib
100%
Clinical Trial
100%
Breast Cancer
44%
Adverse Event
33%
Combination Therapy
33%
Overall Survival
22%
Progression Free Survival
22%
Malignant Neoplasm
22%
Chemotherapy
11%
Pharmaceutical Manufacturing
11%
Solid Malignant Neoplasm
11%
Metastatic Breast Cancer
11%
Tolerability
11%